# An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care

> **NCT06498921** · — · COMPLETED · sponsor: **Bayer** · enrollment: 106 (actual)

## Conditions studied

- Metastatic Hormone-sensitive Prostate Cancer

## Interventions

- **OTHER:** Darolutamide (Nubeqa, BAY1841788) in combination with androgen deprivation therapy (ADT) and docetaxel

## Key facts

- **NCT ID:** NCT06498921
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-15
- **Primary completion:** 2024-09-15
- **Final completion:** 2024-09-15
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2024-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06498921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06498921, "An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06498921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*